Search results for "LPE"

showing 10 items of 493 documents

Two patients with EP300 mutations and facial dysmorphism different from the classic Rubinstein-Taybi syndrome

2009

Rubinstein-Taybi syndrome (RTS) is characterized by mental retardation, broad thumbs and great toes and a recognizable craniofacial phenotype. Causative mutations have been described in the CREBBP and EP300 genes. Here we present a 19-year-old woman and an unrelated 3-year-old boy, both with broad thumbs and halluces, but with facial aspects distinct from those of typical RTS. The woman had a marked learning disability, but no mental retardation. We identified a de novo c.7100delC mutation in EP300 (which predicts p.P2366RfsX35) in the woman and an apparently de novo c.638delG mutation in the boy, which predicts p.G213EfsX6. Mutations in EP300 are a known but rare cause of RTS. Only five ot…

AdultMaleMicrocephalymedicine.medical_specialtyMedizinmedicine.disease_causeRetrognathiaGeneticsmedicineHumansCraniofacialEP300Genetics (clinical)Rubinstein-Taybi SyndromeGeneticsMutationRubinstein–Taybi syndromebusiness.industrymedicine.diseasePhenotypeDermatologyPalpebral fissureChild PreschoolMutationFemalebusinessE1A-Associated p300 Protein
researchProduct

The behaviour of OKT3-, OKT4- and OKT8-positive cells during phases of elevated spontaneous chemiluminescence activity (CL-A) in multiple sclerosis p…

1987

The chemiluminescence activity (CL-A; synonym = burst activity, BA) and the percentage of OKT3-, OKT4- and OKT8-positive peripheral blood cells were serially examined in four control persons and in eight patients with multiple sclerosis. When the OKT values obtained in phases of increased CL-A (clinical remission) were compared with those of the control group, the percentage of OKT3-positive cells was reduced (P = 0.014), and that of OKT4-positive cells increased (P = 0.014); there were no significant changes in the percentage of OKT8-positive cells (P = 0.171). After the CL-A had returned to normal values, the OKT4-positive cells remained elevated (P = 0.029), whereas the OKT3- (P = 0.342)…

AdultMalePathologymedicine.medical_specialtyMultiple SclerosisT-Lymphocyteschemical and pharmacologic phenomenaNormal valuesT-Lymphocytes RegulatoryMonocyteslaw.inventionlawInternal medicinemental disordersmedicineHumansChemiluminescencebusiness.industryMonocyteMultiple sclerosishemic and immune systemsT lymphocyteT-Lymphocytes Helper-Inducermedicine.diseasePeripheral bloodEndocrinologymedicine.anatomical_structureNeurologyLuminescent MeasurementsFemaleNeurology (clinical)businesspsychological phenomena and processesJournal of neurology
researchProduct

Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine

2003

INTRODUCTION Melperone, a butyrophenone neuroleptic, is frequently used for its sleep-inducing properties. Despite its common use for more than 30 years, it is not yet characterized regarding its effects on cytochrome P450 s (CYPs). In an open pilot study, effects of melperone on the steady-state blood levels of venlafaxine, a recently introduced serotonin- and noradrenaline reuptake inhibiting antidepressant, were assessed. METHODS The dose-corrected serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed retrospectively in a therapeutic drug-monitoring (TDM) database comprising 94 patients. In addition, three patients received venlafaxine and melperone concomitantly a…

AdultMaleSleep Wake Disordersmedicine.medical_specialtyMelperoneVenlafaxine HydrochlorideVenlafaxinePharmacologyMethylationPharmacokineticsOral administrationCytochrome P-450 CYP2D6 InhibitorsInternal medicineDextrorphanmedicineHumansDrug InteractionsPharmacology (medical)AgedRetrospective StudiesChemistryVenlafaxine HydrochlorideGeneral MedicineDextromethorphanMiddle AgedCyclohexanolsButyrophenonesPsychiatry and Mental healthEndocrinologyCytochrome P-450 CYP2D6Drug Therapy CombinationFemaleDrug MonitoringReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

The cellular immune responses induced in the follow-up of interferon-α treated patients with chronic hepatitis C may determine the therapy outcome

1998

Abstract Background/Aims: To study whether the host's immune response determines viral clearance in chronic hepatitis C, virological markers and antigen-specific T cell reactions were analysed in 30 chronic HCV carriers followed up during interferon-α therapy, 11 untreated anti-HCV positive individuals and 10 healthy controls. Methods: Proliferative T helper cell responses to recombinant HCV core and non-structural antigens were monitored by 3 H-thymidine uptake assay and compared to quantitative viraemia levels and HCV genotypes. Results: Of the 30 treated patients, six had sustained complete responses (20%), another six were transient therapy responders (20%) and 18 were non-responders (6…

AdultMaleT-LymphocytesvirusesHepatitis C virusmedicine.medical_treatmentT cellAlpha interferonHepacivirusBiologyLymphocyte Activationmedicine.disease_causeInterferonmedicineHumansViremiaInterferon alfaAgedHepatologyInterferon-alphavirus diseasesImmunotherapyT helper cellHepatitis C ChronicMiddle AgedVirologyTreatment Outcomemedicine.anatomical_structureImmunologyRNA ViralFemaleHepatitis C AntigensViral loadFollow-Up Studiesmedicine.drugJournal of Hepatology
researchProduct

Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis

1992

The pathogenetic mechanisms underlying the development of reactive arthritis and the functional capacities of synovial T cells specific for Yersinia enterocolitica are still unclear. In this study we have determined the cytokine secretion patterns of 24 CD4+ synovial fluid (SF)-derived T cell clones from 2 patients with Yersinia-induced reactive arthritis, 16 clones specific for different Yersinia antigens and 8 clones as controls. The clones specific for Yersinia antigens predominantly belong to the T helper cell 1 (Th1) subset with production of interferon (IFN)-gamma and interleukin (IL)-2, but no IL-4, whereas SF T cells not reactive with Yersinia antigens produce IL-2, IL-4 and IFN-gam…

AdultMaleYersinia Infectionsmedicine.medical_treatmentT cellImmunologyYersiniaLymphocyte ActivationArthritis ReactiveMicrobiologyInterferon-gammaImmune systemAntigenSynovial FluidmedicineHumansImmunology and AllergyYersinia enterocoliticaYersinia enterocoliticabiologyT-Lymphocytes Helper-InducerT helper cellbiology.organism_classificationmedicine.anatomical_structureCytokineImmunologyInterleukin-2Cytokine secretionInterleukin-4
researchProduct

Immunoregulatory T-lymphocyte subset deficiency in newly diagnosed Type 1 (insulin-dependent) diabetes mellitus

1984

Humoral and cell-mediated disorders in Type 1 (insulin-dependent) diabetes suggest that an imbalance of immunoregulatory T-cell subsets exists. In 23 newly diagnosed (onset less than 3 months) and 21 long-standing Type 1 diabetic patients, T lymphocyte subsets were analyzed using monoclonal antibodies (OKT3, OKT4, OKT8, OKM1). The newly diagnosed patients showed a reduction with a significant difference from healthy controls in total T cells (OKT3+: 58.1 +/- 8.5% versus 70.7 +/- 8.0%), helper/inducer cells (OKT4+: 33.8 +/- 7.0% versus 47.1 +/- 8.3%), suppressor/cytotoxic cells (OKT8+: 18.5 +/- 7.3% versus 32 +/- 6.8%) and monocytes (OKM1+: 11.5 +/- 3.8% versus 19.9 +/- 5.2%) (p less than 0.…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classT-LymphocytesEndocrinology Diabetes and Metabolismchemical and pharmacologic phenomenaNewly diagnosedBiologyMonoclonal antibodymedicine.disease_causeT-Lymphocytes RegulatoryMonocytesAutoimmunityPathogenesisIslets of LangerhansLeukocyte CountDiabetes mellitusInternal medicineInternal MedicinemedicineHumansCytotoxic T cellChildType 1 diabetesImmunologic Deficiency SyndromesAntibodies MonoclonalT-Lymphocytes Helper-InducerT lymphocytemedicine.diseaseDiabetes Mellitus Type 1EndocrinologyFemaleT-Lymphocytes CytotoxicDiabetologia
researchProduct

Ophthalmologic complications after intraoral local anesthesia with articaine.

2000

A series of 14 cases of ophthalmologic complications after intraoral anesthesia of the posterior superior alveolar nerve is presented. The most commonly encountered symptoms were diplopia, mydriasis, palpebral ptosis, and abduction difficulties of the affected eye. In all cases, these effects occurred a few minutes after injection of the anesthetic, followed by complete resolution without sequelae on cessation of the anesthetic effect. The pathogenic mechanism underlying such ophthalmologic disorders is discussed in terms of a possible diffusion of the anesthetic solution toward the orbital region.

AdultMalemedicine.medical_specialtyHorner SyndromeEye Diseasesmedicine.drug_classAnesthesia DentalCarticaineArticaineInjectionsOcular Motility DisordersPtosismedicineMydriasisDiplopiaMaxillary NerveBlepharoptosisHumansLocal anesthesiaAnesthetics LocalGeneral DentistryAgedDiplopiaLocal anestheticbusiness.industryMydriasisMiddle Agedeye diseasesSurgeryPalpebral fissureOtorhinolaryngologyAnesthesiaAnestheticSurgeryFemaleOral Surgerymedicine.symptombusinessmedicine.drugOral surgery, oral medicine, oral pathology, oral radiology, and endodontics
researchProduct

A gelatin-thrombin matrix topical hemostatic agent (Floseal) in combination with harmonic scalpel is effective in patients undergoing total thyroidec…

2016

BACKGROUND: Hemostasis during thyroidectomy is essential; however, the safest, most efficient, and most cost-effective way to achieve this is unclear. This randomized, multicenter, single-blind, prospective study evaluated the efficacy and safety of using different hemostatic approaches in patients undergoing total thyroidectomy. METHODS: Patients aged ≥18 to 70 years were randomized to Floseal + a harmonic scalpel (HS), Floseal alone, HS alone, or standard total thyroidectomy. Primary endpoint was 24-hour drain output. Secondary endpoints included surgery duration and complications. RESULTS: Two hundred and six patients were randomized to Floseal + HS (n = 52), Floseal alone (n = 54), HS a…

AdultMalemedicine.medical_specialtyfood.ingredientmedicine.medical_treatmenthemostatic agent030230 surgeryGelatinHemostaticslaw.invention03 medical and health sciencesHemostatic0302 clinical medicinefoodThrombinRandomized controlled triallawHarmonic scalpelHumansMedicineProspective StudiesProspective cohort studyFloseal; gelatin-thrombin matrix; harmonic scalpel; hemostatic agent; total thyroidectomy;Hemostatic Agentbusiness.industryharmonic scalpelThrombinThyroidectomygelatin-thrombin matrixMiddle AgedSurgical InstrumentsGelatin Sponge AbsorbableSurgerytotal thyroidectomyProspective StudieTreatment Outcome030220 oncology & carcinogenesisHemostasisAnesthesiaThyroidectomyGelatinFemaleSurgerybusinessFlosealHumanmedicine.drug
researchProduct

T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.

2005

SummaryHuman parvovirus B19 is a small non-enveloped DNA virus with an icosahedral capsid consisting of proteins of only two species, the major protein VP2 and the minor protein VP1. VP2 is contained within VP1, which has an additional unique portion (VP1u) of 227 amino acids. We determined the ability of eukaryotically expressed parvovirus B19 virus-like particles consisting of VP1 and VP2 in the ratio recommended for vaccine use, or of VP2 alone, to stimulate, in an HLA class II restricted manner, peripheral blood mononuclear cells (PBMC) to proliferate and to secrete interferon gamma (IFN-γ) and interleukin (IL)-10 cytokines among recently and remotely B19 infected subjects. PBMC reactiv…

AdultMalevirusesImmunologyPeripheral blood mononuclear cellVirusParvoviridae Infections03 medical and health sciencesEpitopesInterferon-gammaAntigenPregnancymedicineParvovirus B19 HumanImmunology and AllergyHumansInterferon gammaPregnancy Complications InfectiousCells Cultured030304 developmental biologyParvoviridae0303 health sciencesImmunity Cellularbiology030306 microbiologyParvovirusHistocompatibility Antigens Class IIInterleukinvirus diseasesT helper cellT-Lymphocytes Helper-InducerOriginal ArticlesMiddle Agedbiology.organism_classificationVirology3. Good healthInterleukin-10Endotoxinsmedicine.anatomical_structureImmunologyLeukocytes MononuclearCapsid ProteinsFemaleCell Divisionmedicine.drugClinical and experimental immunology
researchProduct

Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprot…

1992

SUMMARYAutoantibodies against the human asialoglycoprotein receptor (ASGPR) occur in the sera orpaticnts with autoimmune liver disorders. Live-nfiltrating T cell clones that specifically recognize the ASGPR have been described in patients with autoimmune chronic active hepatitis (A-AH) and primary biliary cirrhosis (PBC). Recently, we have shown that peripheral blood mononuclcar cells (PBMC) from patients with A-AH or PBC but not chronic viral hepatitis secreted ant-SGPR antibodies in vitro. In this study we characterized the influence of live-nfiltrating T cells on the secretion of ASGP-pecific autoantibodies by autologous B cells in cell culture supernatants. T cell clones from liver biop…

AdultT cellCD8 AntigensImmunologyAsialoglycoprotein ReceptorPeripheral blood mononuclear cellAutoimmune DiseasesmedicineImmunology and AllergyHumansReceptors ImmunologicCells CulturedAutoantibodiesHepatitis ChronicbiologyAutoantibodyT lymphocyteT-Lymphocytes Helper-InducerMiddle Agedmedicine.anatomical_structureLiverCell cultureImmunologyCD4 Antigensbiology.proteinAsialoglycoprotein receptorFemaleAntibodyCD8Research ArticleClinical and experimental immunology
researchProduct